Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, 041fa7)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation containing a fixed 5:1 molar ratio of cytarabine and daunorubicin. It is designed to optimize the synergistic delivery of these two cytotoxic agents to leukemia cells while minimizing exposure to healthy tissues. Cytarabine is a nucleoside analog that inhibits DNA synthesis by competing with cytidine for incorporation into DNA and inhibiting DNA polymerase. Daunorubicin is an anthracycline that intercalates between DNA base pairs and inhibits topoisomerase II, leading to DNA strand breaks. Developed by Jazz Pharmaceuticals (following the acquisition of Celator Pharmaceuticals), CPX-351 is approved for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- Vyxeos liposomalCPX 351CPX351CPX-351
02
Targets
DNAPOLA1 (DNA polymerase alpha)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, 041fa7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + cytarabine liposome (Jazz Pharmaceuticals plc, 041fa7).